AU2004271740B2 - Benzothiazole derivatives for the treatment of diabetes - Google Patents

Benzothiazole derivatives for the treatment of diabetes Download PDF

Info

Publication number
AU2004271740B2
AU2004271740B2 AU2004271740A AU2004271740A AU2004271740B2 AU 2004271740 B2 AU2004271740 B2 AU 2004271740B2 AU 2004271740 A AU2004271740 A AU 2004271740A AU 2004271740 A AU2004271740 A AU 2004271740A AU 2004271740 B2 AU2004271740 B2 AU 2004271740B2
Authority
AU
Australia
Prior art keywords
benzothiazol
acetonitrile
pyrimidin
amino
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004271740A
Other languages
English (en)
Other versions
AU2004271740A1 (en
Inventor
Pascale Gaillard
Jean-Pierre Gotteland
Pierre-Alain Vitte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono SA filed Critical Merck Serono SA
Publication of AU2004271740A1 publication Critical patent/AU2004271740A1/en
Assigned to LABORATOIRES SERONO SA reassignment LABORATOIRES SERONO SA Request for Assignment Assignors: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
Assigned to MERCK SERONO SA reassignment MERCK SERONO SA Alteration of Name(s) of Applicant(s) under S113 Assignors: LABORATOIRES SERONO SA
Application granted granted Critical
Publication of AU2004271740B2 publication Critical patent/AU2004271740B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AU2004271740A 2003-09-12 2004-09-08 Benzothiazole derivatives for the treatment of diabetes Ceased AU2004271740B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03102740 2003-09-12
EP03102740.2 2003-09-12
PCT/EP2004/052090 WO2005025567A1 (en) 2003-09-12 2004-09-08 Benzothiazole derivatives for the treatment of diabetes

Publications (2)

Publication Number Publication Date
AU2004271740A1 AU2004271740A1 (en) 2005-03-24
AU2004271740B2 true AU2004271740B2 (en) 2010-10-28

Family

ID=34306921

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004271740A Ceased AU2004271740B2 (en) 2003-09-12 2004-09-08 Benzothiazole derivatives for the treatment of diabetes

Country Status (17)

Country Link
US (2) US20070088017A1 (enExample)
EP (1) EP1696909B1 (enExample)
JP (1) JP5021307B2 (enExample)
AT (1) ATE378047T1 (enExample)
AU (1) AU2004271740B2 (enExample)
CA (1) CA2534314C (enExample)
CY (1) CY1107820T1 (enExample)
DE (1) DE602004010178T2 (enExample)
DK (1) DK1696909T3 (enExample)
ES (1) ES2297494T3 (enExample)
HR (1) HRP20070527T3 (enExample)
IL (1) IL174250A (enExample)
NO (1) NO20061600L (enExample)
PL (1) PL1696909T3 (enExample)
PT (1) PT1696909E (enExample)
SI (1) SI1696909T1 (enExample)
WO (1) WO2005025567A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838522B2 (en) * 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
KR101264820B1 (ko) 2006-08-24 2013-05-22 유니버시티 오브 테네시 리서치 파운데이션 치환된 아실아닐리드 및 그의 사용 방법
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008125518A2 (en) * 2007-04-17 2008-10-23 Merck Serono S.A. Process for the preparation of piperazine benzothiazoles
UA100527C2 (en) * 2007-10-10 2013-01-10 Астразенека Аб Benzothiazoles as ghrelin receptor modulators
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
JP6226978B2 (ja) 2012-07-13 2017-11-08 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）によりアンドロゲン受容体（ａｒ）陽性乳癌を処置する方法
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
CN104903331A (zh) * 2013-01-24 2015-09-09 山东亨利医药科技有限责任公司 Jnk抑制剂
WO2017025980A2 (en) * 2015-08-12 2017-02-16 Shoolineuniversity Of Biotechnology And Management Sciences Novel benzothiazole derivatives with enhanced biological activity
CN115887434B (zh) * 2022-11-23 2024-12-24 四川大学 具有抗氧化作用的药物用于制备治疗多囊卵巢综合征药物的用途
US11970467B1 (en) 2023-10-13 2024-04-30 King Faisal University N′-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound
US11905260B1 (en) 2023-10-13 2024-02-20 King Faisal University N′-(1-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003047570A1 (en) * 2001-12-07 2003-06-12 Applied Research Systems Ars Holding N.V. Benzazole derivatives for the treatment of scleroderma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1176269A (en) * 1981-03-02 1984-10-16 Kazimir Sestanj N-naphthoylglycine derivatives
US4927831A (en) * 1988-10-20 1990-05-22 American Home Products Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
EP1110957A1 (en) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
DE60318567T2 (de) * 2002-04-25 2009-02-19 Laboratoires Serono S.A., Coinsins Piperazinbenzothiazole als wirkstoffe in der behandlung von ischämien und krankheiten des zns-systems

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003047570A1 (en) * 2001-12-07 2003-06-12 Applied Research Systems Ars Holding N.V. Benzazole derivatives for the treatment of scleroderma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEE, Y et al. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, vol.278(5): 2896-2902 *

Also Published As

Publication number Publication date
CY1107820T1 (el) 2013-06-19
AU2004271740A1 (en) 2005-03-24
DE602004010178D1 (de) 2007-12-27
DK1696909T3 (da) 2008-01-02
IL174250A0 (en) 2006-08-01
ES2297494T3 (es) 2008-05-01
ATE378047T1 (de) 2007-11-15
CA2534314C (en) 2012-11-13
JP2007505083A (ja) 2007-03-08
PL1696909T3 (pl) 2008-04-30
HK1096594A1 (en) 2007-06-08
WO2005025567A1 (en) 2005-03-24
HRP20070527T3 (en) 2007-12-31
EP1696909A1 (en) 2006-09-06
US20070088017A1 (en) 2007-04-19
US20140107116A1 (en) 2014-04-17
CA2534314A1 (en) 2005-03-24
SI1696909T1 (sl) 2008-02-29
PT1696909E (pt) 2007-12-21
DE602004010178T2 (de) 2008-09-11
NO20061600L (no) 2006-04-07
IL174250A (en) 2011-01-31
JP5021307B2 (ja) 2012-09-05
EP1696909B1 (en) 2007-11-14

Similar Documents

Publication Publication Date Title
AU2004271740B2 (en) Benzothiazole derivatives for the treatment of diabetes
EP1663193B1 (en) Sulfonamide derivatives for the treatment of diabetes
US10441556B2 (en) Composition containing glibenclamide
SK35196A3 (en) Use of thiazolidinedione derivative and related agents
NO314065B1 (no) Farmasöytisk sammensetning omfattende en insulinsensitivitetsenhancer og etbiguanid ved behandling av diabetes
KR20090088854A (ko) 2-6-(3-아미노-피페리딘-엘-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸-4-플루오로-벤조니트릴의 용도
KR20030059287A (ko) Ｇａｂａ 작용제 및 알도스 리덕타제 억제제의 혼합물
CA2585175A1 (en) Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
CA2283319A1 (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
JP2001039872A (ja) 糖尿病合併症のための組成物と治療方法
EP0292050B1 (en) Improved flunarizine-containing compositions
HK1096594B (en) Benzothiazole derivatives for the treatment of diabetes
WO2007007757A1 (ja) PPARγアゴニストを含有する医薬組成物
KR19990036290A (ko) 비인슐린 의존성 진성 당뇨병 환자에 대한 외인성 인슐린 투여량의 감소 방법
JP2007504201A (ja) 真性糖尿病の治療のためのｐｄｅ４阻害剤の使用
RU2825648C1 (ru) Способы лечения коронавирусных инфекций
EA009192B1 (ru) Способ лечения сахарного диабета типа 2
AU2006270184B2 (en) JNK inhibitors for the treatment of endometreosis
KR20070011329A (ko) 인슐린 저항성 개선제를 함유하는 당뇨병 치료제
SA99200033B1 (ar) هيدرات hydrateمن ملح حمض 5-[N-(2-بيريديل)امينو)ايثوكسي] بنزيل] ثيازوليدين ــ 2 ، 4ــ ديون ) ماليك
JP2005516963A (ja) グリタゾンと４−オキソブタン酸を含む薬剤組成物及びそれの糖尿病治療への使用
BRPI0616055A2 (pt) inibidores de dipeptidil peptidase para o tratamento do diabetes

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: LABORATOIRES SERONO SA

Free format text: FORMER APPLICANT(S): APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 20 MAY 2008 TO 20 JUN 2009 IN WHICH TO REQUEST EXAMINATION HAS BEEN FILED .

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO REQUEST EXAMINATION HAS BEEN EXTENDED TO 20 JUN 2009.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired